INTRODUCTION
Differences in structure between receptor subtypes allow for the design of subtype-selective drugs. In the present study we shift focus from differences in receptor structure towards differences in subsequent intracellular signal propagation to engender tissue-selectivity of drug action. This concept is also addressed as "cell-based functional selectivity" (Kenakin, 2007) or "phenotypic pharmacology" (Nelson and Challiss, 2007) and is based on the stoichiometry and sensitivity of the cellular components driving the cellular response. It should not be confounded with "receptor-based selectivity" or "ligand-induced bias" (Kenakin, 2007) . In contrast to conventional binding selectivity, cell state-dependent signaling will generate selectivity even between tissues endowed with the same receptor subtype. For this principle to work it is crucial to chemically encode agonist sensitivity at a level that discriminates between different states of cellular activity. Such "chemically engineered" context-dependent signaling will be introduced here. As a paradigm we will elucidate why activation of the M 2 muscarinic acetylcholine receptor can be exploited to suppress pain (Matera et al., 2014) , even though this subtype would in principle also mediate dangerous slowing of the heart rate.
Remarkably, even permanently charged muscarinic ligands unable to penetrate the bloodbrain-barrier are powerful analgesics in animal experiments and such peripheral compounds lack unwanted central tremorgenic activity (Barocelli et al., 2001; Matera et al., 2014) . Therefore, permanently charged M 2 -selective agonists should be useful for the treatment of pain disorders. In mammalian hearts, M 2 receptor-signaling is preferentially mediated via activation of inhibitory G proteins (G i/o ), whereas counteracting adrenergic β -receptors activate stimulatory G protein (G s ) signaling (for reviews (Brodde and Michel, 1999; Haga, 2013) ). This functional antagonism converges on the level of intracellular cAMP. Therefore, we hypothesized less effective cholinergic signaling by dualsteric agonists to occur in tissues This article has not been copyedited and formatted. The final version may differ from this version. In order to probe feasibility of this concept, we applied a novel type of agonist engineered to transduce receptor activation with down-tuned efficacy (Bock et al., 2012) . These "dualsteric" (bitopic orthosteric/allosteric) ligands activate the receptor protein from the orthosteric transmitter binding site and simultaneously bind to the receptor's allosteric vestibule thereby hindering the receptor from adopting the fully active state (supplementary Fig. S1 , for review ). The term "dualsteric" illustrates that ligand binding is present at two sites on one and the same receptor protein. receptors. Third, we analyzed the negative chronotropic response in spontaneously beating murine embryonic cardiomyocytes (eCM) after agonist application. The orthosteric agonist oxotremorine M (OxoM), the dualsteric agonist iper-6-phth (I-6-p) and the partial agonist pilocarpine (Pilo) did not fully inhibit acetylcholine release from cholinergic nerve endings of the hippocampus. In contrast to this, all compounds induced full intrinsic efficacy in eCM, i.e. complete silencing of spontaneous beating. The intensity of drug action is well known to depend on the level of receptor expression (Kenakin, 2007; Rajagopal et al., 2011) . However, the functional status of the receptor protein may be also critical. Here, we show that the intrinsic efficacy of the dualsteric compound for slowing spontaneously beating of eCM declines with elevated intracellular cAMP. Additionally, left ventricular catheter This article has not been copyedited and formatted. The final version may differ from this version. The dualsteric agonists were kindly provided from Prof. DeAmici and Prof. Holzgrabe.
Synthesis of the dualsteric agonists iper-6-phth (I-6-p; (Antony et al., 2009) ) and iper-8-phth
(I-8-p; (Bock et al., 2012) ) is described elsewhere.
Cell culture
We used Flp-In TM -Chinese Hamster Ovary cells (R75807, Invitrogen) stably expressing the human M 2 receptor (CHO-hM 2 ) and the human lung fibroblast cell line MRC-5 (CCL-171, ATCC). Cell lines were used in experiments until reaching passage 50 and 10 for CHO-hM 2 and MRC-5, respectively. MRC-5 and CHO cells were negatively tested for mycoplasma contamination. Both cell lines were cultured as described previously .
Animals
Wild-type mice (C57BL/6 and CD1 strain) of both sexes were used in the described experiments. Mice (Charles River; Sulzfeld, Germany) were housed in isolated ventilated cages at 24°C with a 12:12-h light-dark cycle. Animals taken for organ and embryo isolation were killed by cervical dislocation. Animal experiments were approved by the responsible federal state authority (Landesamt fuer Natur-, Umwelt-und Verbraucherschutz NordrheinWestfalen).
This article has not been copyedited and formatted. The final version may differ from this version. (Antony et al., 2009; Schröder et al., 2010; Schrage et al., 2013) .
Inhibition of acetylcholine release
Superfusion studies on hippocampal brain slices of female eight-week old CD1 mice were performed as described earlier (Schulte et al., 2012) . Briefly, slices (0.3 mm thick, diameter 2 mm) were preincubated with [ mA, 2 ms) were applied after 40 min (S 1 ) and 90 min (S 2 ) of superfusion. Fractional rates of tritium overflow without (S 1 ) and with agonist (S 2 ) were calculated and agonist-induced inhibition of transmitter release finally expressed as S 2 /S 1 ratio. OxoM and I-6-p were tested on brain slices obtained from three and seven independent isolations, respectively. Pilo was tested in a supramaximal concentration of 1 mM on two brain slices obtained from the same isolation.
Beating frequency of cardiomyocytes
This article has not been copyedited and formatted. The final version may differ from this version. Atrial cardiomyocytes were enzymatically isolated by collagenase treatment according to Fleischmann et al. (Fleischmann et al., 2004 ) from murine embryonic mid-stage hearts (mouse strain CD1; sex of the used embryo "unknown"). After isolation on day 13.5-16.5 from female pregnant mice, cells were plated on sterile gelatine-coated glass coverslips and kept in the incubator (37 °C, 5% CO 2 ) for 48 h. On the day of experiment, coverslips were transferred into a temperature-controlled recording device (37 °C) and superfused with increasing agonist-containing buffer solution (140 mM NaCl, 5.4 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM HEPES and 10 mM glucose; pH 7.4 with NaOH). As cellular read-out, the negative chronotropic effect in spontaneously beating cardiomyocytes was measured by videomicroscopy as described previously (Dobrowolski et al., 2008) . Movies of beating cardiomyocytes were recorded with a Sony XCD-X710 camera at 30 frames/s, and beating areas were analyzed off-line with a custom-written software (Labview 7.1 and IMAQ, National Instruments, Austin, TX, USA). Test compound effect was determined as the average frequency over the last 30 s in steady-state and was normalized to baseline frequency.
Each agonist was tested at least in three independent experiments.
Cardiomyocyte sarcomere shortening
Ventricular cardiomyocytes were prepared from male adult mouse hearts (mouse strain C57BL/6, age: 20-25 weeks) as described previously (Tiemann et al., 2003) 
Left ventricular catheter measurements (LVCM)
Measurements were performed as described previously (Wenzel et al., 2012) . Briefly, female mice (age: 8-12 weeks) of the CD1 strain were anesthetized by inhalation of 1% isoflurane and 0.6 l/min O 2 . The right carotid artery was exposed and a small catheter (1F, Millar) was (AD Instruments, Spechbach, Germany). For analysis maximal systolic pressures and the heart rate before and 2 min after injection were compared. Based on earlier publications (Barocelli et al., 2001; El Beheiry et al., 2011) , a sample size of n ≥ 5 was elected.
Experiments were performed without randomization; no blinding was performed.
Dynamic Mass Redistribution (DMR)
To detect GPCR signaling on whole-cell level in CHO-hM 2 and MRC-5, we used label-free biosensor technology based on dynamic mass redistribution (DMR) (Schröder et al., 2010) .
The principle of DMR was described elsewhere in detail for CHO (Schröder et al., 2011) and MRC-5 cells (Lamyel et al., 2011) . Experiments were conducted in Hank's balanced Salt maximal response between 0 and 1800 seconds.In CHO-hM 2 , agonists were additionally tested in presence of 10 µM FSK. Independent experiments were performed in triplicate. As reported previously for CHO cells (Schröder et al., 2011) , concentration-effect curves of MRC-5 were almost independent from the time point of DMR reading (supplementary Fig.   S5 ). Independent experiments were conducted at least three times in triplicate or quadruplicate according to earlier publications (Schröder et al., 2010; Bock et al., 2012; Schrage et al., 2013) .
Radioligand binding assays
[ 3 H]NMS dissociation assay: Two-point [ 3
H]NMS dissociation experiments with membrane
homogenates expressing muscarinic receptors were conducted in 5 mM NaKP i buffer (4 mM Na 2 HPO 4 , 1 mM KH 2 PO 4 , pH 7.4) at 23 °C as described previously (Huang et al., 2005) .
Preparation of membrane homogenates (CHO and MRC-5) and cardiac tissue homogenates
(murine ventricular tissue from adult C57BL/6 mice; age and sex "unknown") was conducted according to Schrage et al. (Schrage et al., 2013) and Keller et al. (Keller et al., 2015) , respectively. Radioligand binding experiments were conducted at least three times in duplicate; sample size was elected on grounds of earlier publications (Bock et al., 2012; Schrage et al., 2013) . Fig. S3A ). Then, cellular cAMP was related to the protein content of the cells determined according to Lowry using human serum albumin as a standard (Lowry et al., 1951) . Experiments were performed in triplicate using cells in suspension.
Statistics and data analysis
Data are shown as mean values ± standard error of the mean (SEM) for n independent observations. F-tests were performed to check the variance between statistically tested groups; no difference was detected. Based on the assumption of normal data distribution, comparison of means was performed using Student's two-side t-tests (paired and unpaired) or one-way analysis of variance (ANOVA). ANOVA was followed by Dunnett's or Tukey's post-test, as appropriate, with p < 0.05 taken as significant.
All data were analyzed using Prism 6.0 (GraphPad Software, San Diego, CA, USA).
Functional and binding data were analyzed using a four-parameter logistic function yielding the inflection point (IC 50 ), the upper and lower plateau, and the slope factor of the curves. In case of functional experiments, the inflection point represents the potency (EC 50 ) and the upper plateau describes the maximal inducible effect (E max ). If the observed slope factors did not differ significantly from unity (F-test, p > 0.05), the slope factor was constrained to 1.
This article has not been copyedited and formatted. The final version may differ from this version. (Cheng and Prusoff, 1973) .
Receptor density (B max ) was calculated from IC 50 values according to DeBlasi et al. (DeBlasi et al., 1989) .
Additionally, mean values from DMR experiments with CHO-hM 2 and MRC-5 cells were
analyzed by the operational model of agonism (Black and Leff, 1983) to estimate the coupling efficiency as described earlier (Rajagopal et al., 2011; Schrage et al., 2013) 
In this equation, E is the response, E max is the maximal response of the system (determined by the full agonist OxoM), τ is the coupling efficacy between the agonist/receptor complex and its downstream signaling partners, K A is the agonist's dissociation binding constant, and [A] is the concentration of agonist.
The maximum effect of an agonist predicted from the coupling efficiency was calculated according to equation 2 (Black et al., 2010) and plotted as a theoretical curve in Fig. 5 (lower panel) with E max of the system fixed to 1.
This article has not been copyedited and formatted. The final version may differ from this version. 
RESULTS

The cellular context determines the intensity of muscarinic M 2 receptor signaling
Ligands are traditionally subdivided in full agonists, partial agonists or antagonists depending on their ability to elicit a receptor-mediated physiological or pharmacological response (Stephenson, 1956) . It is important to note that the amount of detectable receptor activation is system-and assay dependent (Langmead and Christopoulos, 2013) . In systems with high receptor density and/or assays with significant signal amplification, full and partial agonists can induce the same maximum effect (Rajagopal et al., 2011; Schrage et al., 2015) . Therefore, we determined the intrinsic efficacy of muscarinic agonists first in an assay with low signal amplification using receptor homogenates of CHO-hM 2 cells. [
S]GTPγS-accumulation is a
functional readout to detect inhibitory G protein activation that is close to the receptor and directly linked to the agonist-induced receptor activation (Fig. 1A ) (Milligan, 2003) . The orthosteric activator OxoM is known to be as effective as acetylcholine and represents a full agonist . Pilo is known to induce less G protein activation via the M 2 receptor than OxoM (VanGelderen et al., 1996) and was employed as a "partial agonist". In contrast to OxoM, which elicited maximal G protein activation, Pilo and the prototypal dualsteric agonist I-6-p induced only effects of 60 ± 3% and 75 ± 3%, respectively (Fig. 1B) .
The potency for receptor mediated [ calcium channels that are involved in the regulation of neutrotransmitter release (Fig. 1C ) (Caulfield, 1993; Shapiro et al., 1999) . The M 2 receptor subtype is known to be the dominant muscarinic autoreceptor in the hippocampus (Zhang et al., 2002) . As expected, all agonists failed to fully inhibit acetylcholine release in the hippocampal brain slices (Fig. 1D) ; even iperoxo, an agonist with supraphysiological efficacy , did not fully inhibit acetylcholine release (Etscheid et al., 2014) . Therefore, the effect of OxoM was considered as the maximum inducible effect in this system. Compared to OxoM, the dualsteric ligand I-6-p was clearly less effective and behaved as a weak partial agonist (Fig.   1D ). Due to the already low effect of I-6-p, Pilo was only tested in the concentration of 1 mM and was as effective as I-6-p. In comparison to [ 35 S]GTPγS-accumulation experiments, potencies were shifted to higher concentrations but were again in the same range for OxoM and I-6-p (pEC 50 : 6.58 ± 0.27 and 4.79 ± 0.80 for OxoM and I-6-p, respectively). Because muscarinic acetylcholine receptor activation is also known to mediate dangerous slowing of the heart rate ( Fig. 1E) , we next investigated the effect in cardiomyocytes. For this, we measured the agonist-induced negative chronotropic effect on spontaneous beating eCM by videomicroscopy. This assay is an indirect detection method for M 2 receptor activation . Therefore, eCM were superfused with increasing concentrations of test compound. Cumulative administration of either the orthosteric activator OxoM, the partial agonist Pilo or the dualsteric agonist I-6-p caused concentration-dependent lowering of spontaneous beating rates (Fig. 1F ). OxoM and I-6-p possessed similar potencies (pEC 50 :
6.88 ± 0.10 and 6.62 ± 0.10 for OxoM and I-6-p, respectively) and showed full intrinsic efficacy. Even the less potent agonist Pilo (pEC 50 : 5.21 ± 0.12) caused a complete arrest of spontaneous beating. Upon wash-out with agonist-free solution, all tested cells resumed spontaneous beating (OxoM: 94 ± 3 % (n=33), I-6-p: 80 ± 3% (n=34), Pilo: 64 ± 4% (n=36)).
Dualsteric muscarinic agonist action is sensitive to intracellular cAMP in cardiomyocytes
In cardiomyocytes, activation of M 2 receptors leads to inhibition of the adenylyl cyclase via activation of G i/o proteins and hence inhibits formation of the second messenger cAMP (Brodde and Michel, 1999) . Therefore, it is imaginable that the intensity of cellular read-out depends on the basal intracellular cAMP level. To check whether dualsteric agonist action is reduced in case of increased intracellular cAMP in eCM, I-6-p-induced decrease of eCM beating was tested under basal conditions and under sympathetic stimulation (Fig. 2) . Realtime recordings are shown in the upper panels ( Fig. 2A and 2B ), whereas single data points are plotted in the lower panels ( Fig. 2C and 2D ). To mimic sympathetic stimulation, eCM were pretreated with the β -adrenergic agonist isoprenaline (ISO) in combination with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX). The combination of ISO (100 nM) and IBMX (100 µM) provides maximal stimulation of the system (Ji et al., 1999; Malan et al., 2004) . Cardiomyocytes responded with an increase of spontaneous beating rate by at least 15% (15 out of 20 cells; responding cells were plotted in Fig. 2D and their individual response visualized via a connecting line). In comparison to baseline frequency, ISO induced a significant increase in beating frequency (basal: 139 ± 7 bpm vs. ISO/IBMX: 197 ± 11 bpm; mean values ± SEM, p < 0.0001, paired t-test). In the presence of ISO and IBMX, I-6-p failed to achieve full intrinsic efficacy even at concentrations of 10 µM (Fig. 2D) . In contrast, This article has not been copyedited and formatted. The final version may differ from this version. OxoM 10 µM could still completely suppress spontaneous beating. We checked our findings of dualsteric agonist action also in adult ventricular cardiomyocytes by measuring sarcomere shortening as an inotropic response. In the presence of ISO, I-6-p induced significantly less negative inotropy in these cells than the orthosteric agonist OxoM (supplementary Fig. S2 ).
Taken together, these findings are in line with the hypothesis that a given adrenergic tone provides better protection against negative chronotropy and inotropy induced by the dualsteric muscarinic agonist I-6-p compared to the purely orthosteric agonist OxoM.
The dualsteric muscarinic agonist I-6-p engenders superior cardiovascular tolerability in vivo
Systemic administration of muscarinic agonists in mammals is known to cause a pronounced reduction of heart rate and mean arterial pressure (Barocelli et al., 2001; Takakura et al., 2003; Fisher et al., 2004) . To check the cardiodepressive action of the orthosteric agonist OxoM and the dualsteric agonist I-6-p in vivo, left ventricular catheter measurements were carried out in anesthetized mice. Because of their permanent charge both compounds are unlikely to pass the blood-brain-barrier, which rules out central cardiodepressive effects. Both agonists were administered intravenously by bolus injection into the left jugular vein. OxoM was administered at a dose of 100 µg/kg to induce a maximal effect (Barocelli et al., 2001 ).
Based on the mean body weight and blood volume of mice (i.e. 30 g and 4 ml, respectively), this will result in an initial blood concentration of 3 µM. The dualsteric agonist I-6-p was applied at the same concentration as OxoM as both compounds were equipotent in eCM (Fig.   1F ).
Real-time recordings of left ventricular systolic pressure (LVSP, Fig. 3A and 3C ) and heart rate (HR, Fig. 3B and 3D ) revealed a pronounced suppression of cardiovascular function in the case of OxoM, whereas I-6-p was well tolerated. In particular, OxoM was lethal in 60% of the animals, whereas all mice of the I-6-p-group survived. Statistical analysis of cardiac This article has not been copyedited and formatted. The final version may differ from this version. reduction to 40 ± 5% (OxoM) vs. 86 ± 2% (I-6-p), p < 0.001). Due to the small effect of I-6-p, a second dose was administered 10 minutes after the first one. The second application induced no further effect, thus indicating that the applied concentration of I-6-p was maximally active (LVSP: reduction by 10 ± 3% (1st application) vs. reduction by 1 ± 2% (2nd application), HR: reduction by 14 ± 2% (1st application) vs. reduction by 2 ± 1% (2nd application)).
To check the basal β -adrenergic tone of anesthetized mice in our experiments, we applied the Therefore, we hypothesized that I-6-p showed better in vivo cardiovascular tolerability in mice because of a higher sensitivity to the endogenous β -sympathetic tone.
Intracellular cAMP mediates loss of sensitivity to dualsteric muscarinic agonists
Experiments on isolated cardiomyocytes and in anesthetized mice suggested that interventions to increase intracellular cAMP weaken cholinergic G i/o -signaling in the case of the dualsteric ligand I-6-p. For the analysis and quantification of signaling efficiency, we took advantage of CHO cells as recombinant host to recapitulate this signaling paradigm by recombinant expression of the human muscarinic M 2 receptor subtype (CHO-hM 2 , i.e. hM 2 "overexpression" system). Cells were studied in the absence and presence of forskolin (FSK), a direct activator of adenylyl cyclases (Seamon et al., 1981) that increased intracellular cAMP in a concentration-dependent manner (supplementary Fig. S3B ) (supplementary Fig. S3C ).
After FSK-pretreatment (10 µM), that increased intracellular cAMP to the level in human This article has not been copyedited and formatted. The final version may differ from this version. Fig. S4 ).
To quantify muscarinic agonist action on whole cell level in all three different cellular systems (i.e. CHO-hM 2 , CHO-hM 2 + FSK, and MRC-5), we used the label-free optical biosensor Epic ® and measured agonist-induced dynamic mass redistribution (DMR) in living cells (Schröder et al., 2010; Schröder et al., 2011) ; this is outlined in Fig. 4 . To gain deeper insight into how the cellular context influences agonist efficiency, we included the middle-
chain-elongated derivative iper-8-phth (I-8-p). I-8-p is characterized by an increased coupling
efficiency at the expense of less signaling pathway-selectivity compared with I-6-p (Bock et al., 2012) .
In CHO-hM 2 cells, muscarinic agonists induced positive DMR signals with a characteristic peak (real-time recordings, Fig. 4A ) representing M 2 receptor activation (Bock et al., 2012) .
All tested ligands behaved as full agonists under basal conditions, as none of the compounds had a lower maximum effect than the full agonist OxoM (Fig. 4B) . As reported previously, OxoM is as efficacious as the endogenous agonist acetylcholine . In the presence of FSK, the absolute level of OxoM-induced DMR nearly doubled relative to control conditions. Additionally, DMR-signals fanned out and partial agonism emerged for I-6-p and Pilo (Fig. 4D) , whereas efficacy of the middle chain-elongated dualsteric ligand I-8-p did not differ from the efficacy of OxoM (Fig. 4E ).
In MRC-5 cells, test compounds revealed a similar pattern of full/partial-DMR-agonism as found with FSK-pretreated CHO-hM 2 cells ( Fig. 4G and 4H ). However, a switch from full to partial agonism was observed for I-8-p (Fig. 4H) . Regarding the relative potency of each This article has not been copyedited and formatted. The final version may differ from this version. CHO-hM 2 < CHO-hM 2 + FSK < MRC-5 (compare Fig. 4C , 4F, 4G and supplementary Tab. S2). A decrease of potency typically occurs when an agonist switches from full to partial agonism, because a rightward shift of the inflection point indicates a decline of spare receptors in the corresponding systems (Kenakin, 2007; Rajagopal et al., 2011) .
Agonist-encoded coupling efficiency dictates context-sensitivity of action
Experimental findings suggested that the level of intracellular cAMP is critical for dualsteric ligand-induced M 2 receptor activation. Coupling efficiency (τ) determines whether and to which extent a ligand transforms from a full to a partial agonist upon a change of cellular context. Coupling efficiency is a measure that includes the efficacy of an agonist and the sensitivity of the system to agonism (Kenakin, 2007) . To quantify coupling efficiency of the ligands applied in this study, data from DMR experiments (see above) were analyzed according to the operational model of agonism (Black and Leff, 1983) as described before (Rajagopal et al., 2011; Schrage et al., 2013) . In Taken together, the dualsteric building-block design opens an avenue for graded contextsensitive GPCR activation.
Data availability
All relevant data are available from the authors.
DISCUSSION
Muscarinic acetylcholine receptors (mAChRs) regulate the activity of numerous fundamental central and peripheral functions. Therefore, muscarinic agonists and antagonists possess several therapeutic indications and are currently approved for some clinical conditions (for reviews (Wess et al., 2007; Kruse et al., 2014) ). However, the clinical usefulness of these agents is limited by side effects caused by the non-selective activation of all or multiple mAChRs. For example, therapeutic systemic administration of conventional muscarinic agonists is mainly hampered by central tremorgenic activity and peripheral cardiac depression (Barocelli et al., 2001) . It is well known that conventional full agonists evoke profound cardiovascular depression (Barocelli et al., 2001) . It was therefore of particular interest that a novel type of GPCR-activator was recently introduced (Antony et al., 2009 ). Regarding the chemical design, this type of activator is a dualsteric compound consisting of an orthosteric and an allosteric building block, both linked via a hydrocarbon chain (chemical structure, supplementary Fig. S1 ).
Quantification of M 2 receptor-mediated signaling in three different cellular systems (i.e. (i) CHO-hM 2 cells, (ii) hippocampal brain slices, and (iii) embryonic cardiomyocytes) revealed that the intrinsic efficacy of I-6-p was highly system-and assay-dependent, whereas the efficacy of OxoM remained largely stable over all systems. In comparison to direct G protein activation quantified in [ 35 S]GTPγS binding experiments, the efficacy of I-6-p to inhibit neurotransmitter release from cholinergic nerve endings was relatively weak (cf Fig.1D ), whereas spontaneous beating of eCM was completely suppressed (cf Fig.1F ). This powerful effect in eCM might result from a high receptor reserve and/or a strong signal amplification in cardiomyocytes. The term receptor reserve ("spare receptors") addresses the fraction of cellular receptors that is not needed for a maximum response of the system (Kenakin, 2013) .
Of note, we showed that the intrinsic efficacy of the dualsteric agonist I-6-p, in contrast to the This article has not been copyedited and formatted. The final version may differ from this version. Fig. 2 and supplementary Fig. S2 ).
Furthermore, I-6-p induced less cardiac depression in vivo compared to OxoM and did not induce cardiac arrest (Fig. 3) . This good cardiac tolerability of I-6-p makes a clinical application of dualsteric muscarinic agonists more likely than initially expected. One potential indication for dualsteric ligands may be the treatment of pain disorders (Matera et al., 2014) .
Context-sensitive signaling offers a mechanistic explanation as to why the cardiovascular tolerability of I-6-p by far exceeded the tolerability of OxoM in anaesthetized mice. As described by various researchers before (Gehrmann et al., 2000; Rose et al., 2007; El Beheiry et al., 2011; Mabe and Hoover, 2011) , application of the β -blocker metoprolol revealed a significant β -adrenergic tone acting on the mouse heart in our experiments. In consequence, In contrast, muscarinic antagonists have no significant effect on basal HR in mice (Wickman et al., 1998; Mabe and Hoover, 2011) .
Ranking of the applied test compounds according to their coupling efficiencies shows a stable pattern irrespective of the cellular system: OxoM > I-8-p > I-6-p ~ Pilo ( In case of CHO-hM 2 , the sensitivity of the system to agonism was diminished by an increase of intracellular cAMP induced by FSK. As a consequence, compounds with lowest coupling efficiency in CHO-hM 2 were the first that switched from full to partial agonism after FSKpretreatment ( Fig. 5 lower panel: half-filled circles of Pilo (grey) and I-6-p (red)). In case of MRC-5, besides high intracellular cAMP, additionally receptor density was reduced (supplementary Tab. S1). As a consequence, not only Pilo and I-6-p, but additionally I-8-p became a partial agonist (Fig. 4 lower panel, open circles of Pilo (grey), I-6-p (red) and I-8-p (green)).
Taken together, we suggest the following mechanism of context-dependent coupling efficiency: Under conditions of low cAMP levels, a small fraction of activated M 2 receptors will suffice to counterbalance cAMP-mediated actions: high "M 2 receptor reserve" -even M 2 agonists with low signaling efficiency such as Pilo are able to generate a maximum muscarinic effect. With increasing cAMP levels to be counteracted, an increasing fraction of M 2 receptors needs to be activated: reduced sensitivity of the system to agonism or, in other words, less "receptor reserve". This mechanism can also be described as "functional antagonism", if cAMP is increased due to adrenergic counter-regulation (Pyne et al., 1992) . A compound with less intrinsic efficacy for receptor activation, i.e. lower coupling efficiency, such as I-6-p and Pilo then fail to induce full agonism. Pilo behaved similar to I-6-p, but is able to pass the blood-brain-barrier and may exert central nervous side effects such as seizures (Bymaster et al., 2003) .
Furthermore, the design of partial agonists in the past seemed to be fairly random. Now, the novel dualsteric concept allows the design of tailor-made agents for the exploitation of context-dependent signaling via linkage of orthosteric/allosteric building blocks and variation This article has not been copyedited and formatted. The final version may differ from this version. of the length of the hydrocarbon middle chain (Antony et al., 2009; Bock et al., 2012; Bock et al., 2014) .
Irrespective of specific therapeutic perspectives, our study shows that pharmacological modulators can be designed which are sensitive to the functional context of a target.
Commonly, pharmacologically targeted receptors such as the muscarinic acetylcholine receptor species, are classified into subtypes depending on differences in structure (for reviews (Haga, 2013; Kruse et al., 2014) ). Exploitation of context-dependent signaling expands the repertoire for selective pharmacological intervention in that one and the same receptor subtype may reveal different pharmacological phenotypes depending on the functional state of the cell population that harbors the receptor.
In conclusion, dualsteric (orthosteric/allosteric) targeting of muscarinic acetylcholine receptors generates new forms of pharmacological modulation and selectivity. Dualsteric agents were first characterized as signaling pathway-selective ("biased") activators of muscarinic receptors (Antony et al., 2009; Bock et al., 2012) . Very recently, the dualsteric design concept was exploited to achieve the first designed dynamic partial agonists in the field of G protein-coupled receptors (Bock et al., 2014) . Here we introduce context-sensitive signaling as an important mechanism of pharmacological selectivity for clinical application, and we show that capacity to monitor cell function in real time both in vitro and in vivo was key to discovery of this. 
